Stefanik, M.; Valdes, J.J.; Ezebuo, F.C.; Haviernik, J.; Uzochukwu, I.C.; Fojtikova, M.; Salat, J.; Eyer, L.; Ruzek, D.
FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms 2020, 8, 599.
https://doi.org/10.3390/microorganisms8040599
AMA Style
Stefanik M, Valdes JJ, Ezebuo FC, Haviernik J, Uzochukwu IC, Fojtikova M, Salat J, Eyer L, Ruzek D.
FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms. 2020; 8(4):599.
https://doi.org/10.3390/microorganisms8040599
Chicago/Turabian Style
Stefanik, Michal, James J. Valdes, Fortunatus C. Ezebuo, Jan Haviernik, Ikemefuna C. Uzochukwu, Martina Fojtikova, Jiri Salat, Ludek Eyer, and Daniel Ruzek.
2020. "FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells" Microorganisms 8, no. 4: 599.
https://doi.org/10.3390/microorganisms8040599
APA Style
Stefanik, M., Valdes, J. J., Ezebuo, F. C., Haviernik, J., Uzochukwu, I. C., Fojtikova, M., Salat, J., Eyer, L., & Ruzek, D.
(2020). FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms, 8(4), 599.
https://doi.org/10.3390/microorganisms8040599